E-ISSN 2602-3164
EJMI. 2021; 5(4): 500-507 | DOI: 10.14744/ejmi.2021.58025

Options in First Line Management of Metastatic Pancreatic Cancer and the Determinative Role of ECOG Performance Status

Ferhat Ekinci1, Atike Pinar Erdogan1, Serkan Yildirim2, Ahmet Ozveren3
1Department of Medical Oncology, Celal Bayar University, Manisa, Turkey, 2Department of Medical Oncology, Tatvan State Hospital, Bitlis, Turkey, 3Department of Medical Oncology, Private Kent Hospital, İzmir, Turkey

Objectives: It will contribute to the fact that the first-line treatment options of patients with metastatic pancreatic cancer (PC) who apply to the oncology clinic are discussed in the light of the literature and guide the clinicians in making the initial treatment decision. Methods: Patients who were diagnosed with PC in a total of 2 centers between 2010 and 2019 and who were found to have distant organ metastases at the time of diagnosis or during follow-up were included. Patients were categorized into 3 groups in terms of metastatic first line treatments: gemcitabine (Gm), gemcitabine-platinum (cisplatin or carboplatin) (GP) combination and FOLFIRINOX (FX). These three treatment groups were compared in terms of patient with tumor characteristics and progression free survival (PFS) - overall survival (OS). Results: The present study included 355 patients who were admitted to our clinic. The first line therapies received by the patients were analyzed, it was seen that 124 (34.9%) patients received Gm chemotherapy (CT), 43 (12.1%) patients received FX, 138 (38.9%) patients received GP and 18 (5.1%) patients received other regimens. While PFS was 6.1 months in GP areas, it was the shortest with 4.4 months in Gm and the longest with 7.1 months in FX. This difference between the groups was found to be statistically significant (p<0.001). When the data were analyzed in terms of OS; the Gm arm was found to have the shortest OS with 9.6 months. However, GP attracted attention as the treatment that prolonged the OS the most with 15.4 months. This period was calculated as 13.5 months in the FX arm. Again, this difference was found to be statistically significant (p<0.001). Conclusion: The main theme of our study was that ‘Eastern Cooperative Oncology Group’ performance status (ECOG PS) and age were the most important factors in decision making for the management of these patients. As age progresses and PS deteriorates, clinicians move away from the FX regimen. Another important point was that the GP regimen was preferred instead of GnP, probably due to the difficulty in drug supply in our country, and it was found to be superior to other regimens. Keywords: ECOG PS, FOLFIRINOX, Gemcitabine-Platinum, Overall Survival, Pancreatic Cancer

Cite This Article

Ekinci F, Erdogan A, Yildirim S, Ozveren A. Options in First Line Management of Metastatic Pancreatic Cancer and the Determinative Role of ECOG Performance Status. EJMI. 2021; 5(4): 500-507

Corresponding Author: Ferhat Ekinci

Full Text PDF PDF Download